Superior biotech and drug synthesis skills, high quality and vertically integrated assets , differentiated business models and significant cost advantages have enabled Indian companies to occupy the centre stage of the global pharmaceutical market today.

As the Indian pharma companies are thus taking giant strides on the international scene,there is a growing interest the world over about the enormous potential of the Indian pharmaceutical market.

Despite the recent global slowdown, Indian pharma industry has maintained outstanding growth rates, which is forecast to quadruple from US $6.3 billion in 2005 to US $25 billion in 2015.

In their mid-2009 report underlining the important addition of ICSE India, Ernst & Young/Organisation of Pharmaceutical Producers of India (E&Y/OPPI ) has noted that India’s outsourcing sector is growing at 43 per cent , with drug discovery and development segment growing at 65 per cent - well over three times the global average. India is targeting to become one of the top five innovator countries by 2020.

India benefits from a highly skilled workforce and has developed strong expertise in process chemistry. One of the best GMP rated countries in Asia, responsible for around eight per cent of the world pharmaceutical production, India promises a wealth of opportunities for the global pharma industry.

Already a major exporter of FDA compliant APIs, and having gained a reputation for its ability to run successful clinical trials, India has proved itself as an emerging market with both experience and the appropriate expertise.

A long history of chemical manufacturing in the country has already allowed it to become a major manufacturer of generic drugs. Its adoption of patent agreements in 2005 has opened the way for expansion in the manufacture of drugs for the major pharmaceutical companies.

The combination of these factors plus an excellent compliance record, the potential for significant cost savings and the ability to bring new manufacturing facilities on line quickly has made India a very attractive destination for the pharma business from all over the world.

In this context CPhI India 2009 , India's premier pharma networking event and ingredients exhibition being held at the Bombay Exhibition Centre in Mumbai, the commercial capital of India, from December 1 to 3 gives a unique opportunity for the global pharma industry to gather and explore the wealth of opportunities in India.

The remarkable response to CPhI 2009 is a testimony to the continuing growth in the stature of this country on the worldwide pharmaceutical manufacturing stage. The extension of the CPhI franchise into India was in December 2006.CPhI India became the fourth member of the brand’s global event “family” in 2006 and was joined by P-MEC India in 2007. The combined exhibitions are the largest pharma services event in India and South Asia.

CPhI India 2009,is a unique chance to link up with the very best in the industry as they gather to discuss the key issues , trends and developments in one location . With two sister events , ICSE and P-MEC now running alongside, CPhI , a tripartite of events is considered a must attend event for any individual or organization within the pharmaceutical manufacturing community.

It provides the perfect environment for growth, generate new alliances, renew existing partnerships and benefit from the dynamic networking opportunities available to actively drive business forward. It offers them a unique chance to find out what's happening in the industry right now. Each year the exhibition has grown larger with exhibitors and visitors conducting significant levels of business at CPhI.

“India is now moving towards centre stagee in world pharma, with its overall pharma market growing at better than nine per cent - and key segments much faster. CPhI and the co-located events are the natural meeting point that enables a high level of networking and business development across the academic, development, R&D, services and manufacturing communities”, said CPhI India Event Director Annemieke Timmers.

According to M Gandhi ,Managing Director ,UBM India Ltd, “this unique combination of three umbrella events will showcase manufacturing and product capabilities of high values and is a convergence of companies investing in technology , applications development and sophisticated manufacturing capacities.”

The events are jointly organised by UBM International Media and sister company UBM India Pvt. Ltd.

CPhI India has attracted a great number of high profile visitors including industry professionals from general management,marketing & sales, purchasing, production, quality control, engineering & R& D. decision makers from the entire chemical & pharmaceutical industry searching for new products, services & deals.

Visiting CPhI India on the one hand enables a pharma professional to learn everything about the Indian pharma market i.e. to discover the latest innovations, technologies, trends and developments in the industry and on the other enables him access one of the world's fast growing pharmaceutical markets. It also helps him to find all pharmaceutical ingredients, outsourcing, equipment and bio-solutions needs in one location. Moreover it enables him to meet the key pharma professionals from India and many other countries such as the US, Spain, China and the UK and also access co-located events ICSE India, P-MEC India and BioPh India.

In conjunction with CPhI India, the addition of ICSE India and P-MEC India completes an integrated and proven trio of pharmaceutical events for the fast-growing and increasingly influential South Asia region.

Dedicated to the contract services part of the pharmaceutical manufacturing process,ICSE India, with emphasis on the very fast-growing outsourcing and contract services sector is the latest addition to CPhI India 2009.Global pharmaceutical companies are looking to India as an international hub for contract research and manufacturing even as pharmaceutical outsourcing in India is on the increase.

The Pharmaceutical Machinery and Equipment Convention, P-MEC has proved to be an invaluable opportunity for exhibitors to meet new and existing clients, to find and approach new markets and to stay abreast of new developments in pharmaceutical manufacturing.

In addition to high quality exhibitors, the 2009 events also include another new launch BioPh India which will focus on the convergence of technologies and business models in pharma and healthcare biotechnology – especially across the common interest areas of innovation,product development, clinical trials, manufacturing and supply logistics.

The tremendous growth of the Indian pharma industry will figure strongly in the major conferences complementing the exhibitions. These will begin with the Indian Pharma Summit on November 30 at Grand Hyatt hotel , Mumbai focusing on: “The future of India Pharma – India Pharma Vision 2020” addressing the issues, opportunities and challenges for India as an emerging global pharma hub.

The event will be chaired by Ashok Kumar, Secy. Dept. of Pharmaceuticals and co-chaired by Glenn Saldhana, Chairman, Ficci National Pharmaceuticals Committee & MD and CEO, Glenmark Pharmaceuticals.

Staged alongside the first two days of CPhI India, in the BioPh pavilion at the Bombay Exhibition Centre, Biosimilars India 2009 will cover a wide range of topics in 17 sessions across three half-day modules.

“With the BioPh India and ICSE India launches and a strong conference programme adding to a high level of pre-registrations, all our indications are that this year in Mumbai will see our strongest Indian events so far”, says ICSE, BioPh and P-MEC Event Director Haf Cennydd.